Table 1. Comparison between groups in terms of clinicopathologic characteristics.

Variable	Total		ER+/PgR+/HER2-		ER+/PgR-/HER2-
	No.	%	No.	%	No.	%	P
Gender
Male	5	0.3%	1	0.1%	4	1.1%	0.003
Female	1517	99.7%	1155	99.9%	362	98.9%
Age, years
Range	22–93		22–93		24–85
<60	1139	74.8%	884	76.5%	255	69.7%	0.009
≥60	383	25.2%	272	23.5%	111	30.3%
Histologic grade
I/ II	1160	76.2%	921	79.7%	239	65.3%	<0.0001
III	362	23.8%	235	20.3%	127	34.7%
Tumour size, cm
T<2	584	38.4%	446	38.6%	138	37.7%
2≤T<5	922	60.6%	704	60.9%	218	59.6%	0.001
T≥5	16	1.1%	6	0.5%	10	2.7%
LN status
pN0 (none)	912	59.9%	685	60.1%	227	64.1%
pN1 (1–3 LN)	391	25.7%	320	28.1%	71	20.1%
pN2 (4–9 LN)	128	8.4%	97	8.5%	31	8.8%	0.001
pN3 (≥10 LN)	62	4.1%	37	3.2%	25	7.1%
pNX a	29	1.9%	17	-	12	-
LVI
Negative	945	62.1%	717	62.0%	228	62.3%	0.926
Positive	577	37.9%	439	38.0%	138	37.7%
Ki-67, %
1–19	591	38.8%	479	41.4%	112	30.6%	<0.0001
≥20	931	61.2%	677	58.6%	254	69.4%

^aPatients with unknown LN status underwent lumpectomy or conserving surgery.